Author reply: To PMID 24393349

Ophthalmology. 2015 Mar;122(3):e19. doi: 10.1016/j.ophtha.2014.08.010.

Authors

Sophie J Bakri¹, Darius M Moshfeghi², Steve Francom³, Amy Chen Rundle³, Daniel S Reshef³, Paul P Lee⁴, Carol Schaeffer³, Roman G Rubio³, Phillip Lai³

Affiliations

¹ Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. Electronic address: bakri.sophie@mayo.edu.
² Byers Eye Institute at Stanford University, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California.
³ Genentech Inc., South San Francisco, California.
⁴ Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan.

PMID: 25703472
DOI: 10.1016/j.ophtha.2014.08.010

No abstract available

Publication types

Letter
Comment

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Female
Humans
Intraocular Pressure / physiology*
Male
Wet Macular Degeneration / drug therapy*

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized